Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
I-Mab
Biotech
I-Mab pauses Sanofi-partnered prospect to focus on CLDN18.2
I-Mab has made a pipeline pivot, pausing work on an asset Sanofi bought into last year to focus on its play for the congested CLDN18.2 space.
Nick Paul Taylor
Jan 6, 2025 8:34am
Chutes & Ladders—Gilead's Merdad Parsey goes, Cassava loses CEO
Jul 19, 2024 8:00am
Lonza lands new CEO—Chutes & Ladders
Apr 5, 2024 8:30am
I-Mab sheds China footprint to transform into US-based biotech
Feb 7, 2024 8:50am
AbbVie axes I-Mab pact to exit fast-thinning race for CD47 space
Sep 25, 2023 7:30am
Genexine's weekly growth hormone equal to Novo shot in phase 3
Aug 31, 2023 6:00am
